Prognostic impact of lymphovascular invasion and C-MET overexpression in resected stage IB NSCLC

Aim/Background: In stage IB non-small cell lung cancer (NSCLC), prognostic factor is not well known and administration of adjuvant treatment is controversial. The C-MET is known to be associated with the pathogenesis and progression of NSCLC. Our purpose was to evaluate the impact of clinicopathological characteristics and C-MET on recurrence free survival (RFS) and cancer-specific survival (CSS) in patients with stage IB NSCLC, undergoing surgical resection.Methods: From 2005 to 2013, 115 patients who underwent complete resection with pathological stage IB were enrolled. We retrospectively reviewed clinicopathological data and performed immunohistochemistry with anti-MET monoclonal antibody in tissue microarrays. RFS and CSS were evaluated in patients depending on clinicopathological factors and C-MET status.Results: The median age of 115 patients was 65 years (range: 32–82 years). The patients comprised of 78 men (68%) and 37 women (31%). The histological types were adenocarcinoma (n = 77), squamous cell carcinoma (n = 32), others (n = 6). Thirty four patients relapsed and twenty four died of cancer progression. On the univariate analysis, lymphovascular invasion (LVI) (P =.003) and C-MET overexpression (P =.014) were significantly associated with decreased RFS. Meanwhile, smoking (P =.029) and LVI (P =.040) were correlate with shortened CSS. C-MET overexpression (P =.130) were not associated with CSS. However, in larger tumor than median size (>3.5cm), C-MET overexpression (P =.039) had a relation with reduced CSS. In multivariate analysis, LVI (RFS: P =.017) and C-MET (RFS: P = 0.040) were negative independent prognostic factor for RFS, but not significant for CSS. Subgroup assessments according to LVI and C-MET co-positivity were performed with univariate and multivariate analyses. Co-presence of LVI and C-MET overexpression was a significant negative prognostic factor for CSS (P =.023) as well as RFS (P =.002) in resected stage IB NSCLC.Conclusions: Our data indicates that stage IB NSCLC patients with LVI and C-MET overexpression showed poor survival outcome and adjuvant chemotherapy should be strongly recommended for these patients, especially with co-presence of LVI and C-MET overexpression.Disclosure: All authors have declared no conflicts of interest. Aim/Background: In stage IB non-small cell lung cancer (NSCLC), prognostic factor is not well known and administration of adjuvant treatment is controversial. The C-MET is known to be associated with the pathogenesis and progression of NSCLC. Our purpose was to evaluate the impact of clinicopathological characteristics and C-MET on recurrence free survival (RFS) and cancer-specific survival (CSS) in patients with stage IB NSCLC, undergoing surgical resection. Methods: From 2005 to 2013, 115 patients who underwent complete resection with pathological stage IB were enrolled. We retrospectively reviewed clinicopathological data and performed immunohistochemistry with anti-MET monoclonal antibody in tissue microarrays. RFS and CSS were evaluated in patients depending on clinicopathological factors and C-MET status. Results: The median age of 115 patients was 65 years (range: 32–82 years). The patients comprised of 78 men (68%) and 37 women (31%). The histological types were adenocarcinoma (n = 77), squamous cell carcinoma (n = 32), others (n = 6). Thirty four patients relapsed and twenty four died of cancer progression. On the univariate analysis, lymphovascular invasion (LVI) (P =.003) and C-MET overexpression (P =.014) were significantly associated with decreased RFS. Meanwhile, smoking (P =.029) and LVI (P =.040) were correlate with shortened CSS. C-MET overexpression (P =.130) were not associated with CSS. However, in larger tumor than median size (>3.5cm), C-MET overexpression (P =.039) had a relation with reduced CSS. In multivariate analysis, LVI (RFS: P =.017) and C-MET (RFS: P = 0.040) were negative independent prognostic factor for RFS, but not significant for CSS. Subgroup assessments according to LVI and C-MET co-positivity were performed with univariate and multivariate analyses. Co-presence of LVI and C-MET overexpression was a significant negative prognostic factor for CSS (P =.023) as well as RFS (P =.002) in resected stage IB NSCLC. Conclusions: Our data indicates that stage IB NSCLC patients with LVI and C-MET overexpression showed poor survival outcome and adjuvant chemotherapy should be strongly recommended for these patients, especially with co-presence of LVI and C-MET overexpression. Disclosure: All authors have declared no conflicts of interest.